BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
December 05, 2022 07:00 ET | BioRestorative Therapies, Inc
-- Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones-- MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....